CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

Allogeneic stem cell transplantation (alloSCT) is a potentially curative therapeutic option for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Disease relapse occurs in 35-45% of patients following alloSCT, and is the most frequent cause of treatment failure and mortality [1-4]. Moreover, relapse after alloSCT is associated with poor prognosis despite salvage chemotherapy, donor lymphocyte infusions, and/or second transplants [4].

Source: Biology of Blood and Marrow Transplantation - June 20, 2018 Category: Hematology Authors: Marcos de Lima, Betul Oran, Richard E. Champlin, Esperanza B. Papadopoulos, Sergio A. Giralt, Bart L. Scott, Basem M. William, Joel Hetzer, Eric Laille, Becky Hubbell, Barry S. Skikne, Charles Craddock Source Type: research